[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f9AtiM77n9FjVumqYmcNsmKxWG6ZwvUUXVvAjG7PwjdQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":57,"rows":64},"Istituto Auxologico Italiano",[4],200,false,63,2,54521,4,179,[14,17,20,23,26,29,31,34],{"name":15,"count":16},"Obesity",33,{"name":18,"count":19},"Anorexia Nervosa",15,{"name":21,"count":22},"Hypertension",10,{"name":24,"count":25},"Parkinson Disease",8,{"name":27,"count":28},"Amyotrophic Lateral Sclerosis",7,{"name":30,"count":28},"Stroke",{"name":32,"count":33},"Osteoporosis",6,{"name":35,"count":33},"Multiple Sclerosis",[37,42,47,52],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT06307990","Understanding, Diagnosis and Monitoring of Thyroid Hormone Action Defects","2025-10-31","NGS sequencing",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT05759624","Vesiculogenesis in Children With GH Deficiency (VESCIGHTP)","2025-12-31","rhGH",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT07295470","Sleep and Activity For Eating Disorders","2027-05","Collection of biological parameters",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT05766098","Definition of Mutational Profile of Papillary Thyroid Tumors by Mass-ARRAY","2027-10-30","Genotyping",[58,59,60,61,62,63],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[65,88,111,133,158,197,215,240,267,285,312,330,358,376,403,421,447,465,490,515,539,565,589,615,633,658,683],{"intervention":46,"totalTrials":66,"cells":67},1,{"EARLY_PHASE1":68,"PHASE1":71,"PHASE2":73,"PHASE3":75,"PHASE4":77,"NA":79},{"trials":69,"activeCount":70},[],0,{"trials":72,"activeCount":70},[],{"trials":74,"activeCount":70},[],{"trials":76,"activeCount":70},[],{"trials":78,"activeCount":70},[],{"trials":80,"activeCount":66,"soonestReadout":45},[81],{"nctId":43,"briefTitle":44,"status":82,"phases":83,"primaryCompletion":45,"completion":45,"start":84,"enrollment":22,"conditions":85,"interventions":87},"ACTIVE_NOT_RECRUITING",[],"2022-06-24",[86],"GH Deficiency",[46],{"intervention":41,"totalTrials":66,"cells":89},{"EARLY_PHASE1":90,"PHASE1":92,"PHASE2":94,"PHASE3":96,"PHASE4":98,"NA":100},{"trials":91,"activeCount":70},[],{"trials":93,"activeCount":70},[],{"trials":95,"activeCount":70},[],{"trials":97,"activeCount":70},[],{"trials":99,"activeCount":70},[],{"trials":101,"activeCount":66,"soonestReadout":40},[102],{"nctId":38,"briefTitle":39,"status":103,"phases":104,"primaryCompletion":40,"completion":105,"start":106,"enrollment":107,"conditions":108,"interventions":110},"RECRUITING",[],"2026-01-31","2023-01-01",150,[109],"Resistance, Thyroid Hormone",[41],{"intervention":56,"totalTrials":66,"cells":112},{"EARLY_PHASE1":113,"PHASE1":115,"PHASE2":117,"PHASE3":119,"PHASE4":121,"NA":123},{"trials":114,"activeCount":70},[],{"trials":116,"activeCount":70},[],{"trials":118,"activeCount":70},[],{"trials":120,"activeCount":70},[],{"trials":122,"activeCount":70},[],{"trials":124,"activeCount":66,"soonestReadout":55},[125],{"nctId":53,"briefTitle":54,"status":103,"phases":126,"primaryCompletion":55,"completion":127,"start":128,"enrollment":129,"conditions":130,"interventions":132},[],"2027-12-31","2019-01-08",600,[131],"Papillary Thyroid Cancer",[56],{"intervention":51,"totalTrials":66,"cells":134},{"EARLY_PHASE1":135,"PHASE1":137,"PHASE2":139,"PHASE3":141,"PHASE4":143,"NA":145},{"trials":136,"activeCount":70},[],{"trials":138,"activeCount":70},[],{"trials":140,"activeCount":70},[],{"trials":142,"activeCount":70},[],{"trials":144,"activeCount":70},[],{"trials":146,"activeCount":66,"soonestReadout":50},[147],{"nctId":48,"briefTitle":49,"status":148,"phases":149,"primaryCompletion":50,"completion":150,"start":151,"enrollment":152,"conditions":153,"interventions":157},"NOT_YET_RECRUITING",[63],"2027-07","2026-02",75,[154,18,155,156],"Eating Disorders","Bulimia Nervosa","Binge Eating Disorder",[51],{"intervention":159,"totalTrials":9,"cells":160},"Alendronate",{"EARLY_PHASE1":161,"PHASE1":163,"PHASE2":165,"PHASE3":167,"PHASE4":181,"NA":195},{"trials":162,"activeCount":70},[],{"trials":164,"activeCount":70},[],{"trials":166,"activeCount":70},[],{"trials":168,"activeCount":70},[169],{"nctId":170,"briefTitle":171,"status":172,"phases":173,"primaryCompletion":174,"completion":175,"start":176,"enrollment":177,"conditions":178,"interventions":180},"NCT01812551","Treatment of Low Bone Density in Cystic Fibrosis.","COMPLETED",[61],"2006-07","2007-07","2002-10",171,[32,179],"Cystic Fibrosis",[159],{"trials":182,"activeCount":70},[183],{"nctId":184,"briefTitle":185,"status":172,"phases":186,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":191,"interventions":193},"NCT02417389","Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism",[62],"2011-10","2012-12","2008-05",22,[192,32],"Hyperparathyroidism, Primary",[194,159],"cinacalcet",{"trials":196,"activeCount":70},[],{"intervention":194,"totalTrials":66,"cells":198},{"EARLY_PHASE1":199,"PHASE1":201,"PHASE2":203,"PHASE3":205,"PHASE4":207,"NA":213},{"trials":200,"activeCount":70},[],{"trials":202,"activeCount":70},[],{"trials":204,"activeCount":70},[],{"trials":206,"activeCount":70},[],{"trials":208,"activeCount":70},[209],{"nctId":184,"briefTitle":185,"status":172,"phases":210,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":211,"interventions":212},[62],[192,32],[194,159],{"trials":214,"activeCount":70},[],{"intervention":216,"totalTrials":66,"cells":217},"all approved antihypertensive drugs; all approved statins",{"EARLY_PHASE1":218,"PHASE1":220,"PHASE2":222,"PHASE3":224,"PHASE4":226,"NA":238},{"trials":219,"activeCount":70},[],{"trials":221,"activeCount":70},[],{"trials":223,"activeCount":70},[],{"trials":225,"activeCount":70},[],{"trials":227,"activeCount":70},[228],{"nctId":229,"briefTitle":230,"status":172,"phases":231,"primaryCompletion":232,"completion":233,"start":234,"enrollment":6,"conditions":235,"interventions":237},"NCT01563731","Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives",[62],"2020-12-31","2021-03-31","2013-04",[30,236,21],"Transient Ischemic Attack",[216],{"trials":239,"activeCount":70},[],{"intervention":241,"totalTrials":66,"cells":242},"Telmisartan",{"EARLY_PHASE1":243,"PHASE1":245,"PHASE2":247,"PHASE3":249,"PHASE4":251,"NA":265},{"trials":244,"activeCount":70},[],{"trials":246,"activeCount":70},[],{"trials":248,"activeCount":70},[],{"trials":250,"activeCount":70},[],{"trials":252,"activeCount":70},[253],{"nctId":254,"briefTitle":255,"status":172,"phases":256,"primaryCompletion":257,"completion":258,"start":259,"enrollment":260,"conditions":261,"interventions":263},"NCT01830530","HIGH Altitude CArdiovascular REsearch in the ANDES",[62],"2012-09","2012-10","2012-05",100,[21,262],"High Altitude",[241,264],"Nifedipine",{"trials":266,"activeCount":70},[],{"intervention":264,"totalTrials":66,"cells":268},{"EARLY_PHASE1":269,"PHASE1":271,"PHASE2":273,"PHASE3":275,"PHASE4":277,"NA":283},{"trials":270,"activeCount":70},[],{"trials":272,"activeCount":70},[],{"trials":274,"activeCount":70},[],{"trials":276,"activeCount":70},[],{"trials":278,"activeCount":70},[279],{"nctId":254,"briefTitle":255,"status":172,"phases":280,"primaryCompletion":257,"completion":258,"start":259,"enrollment":260,"conditions":281,"interventions":282},[62],[21,262],[241,264],{"trials":284,"activeCount":70},[],{"intervention":286,"totalTrials":66,"cells":287},"enalapril",{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":292,"PHASE3":294,"PHASE4":296,"NA":310},{"trials":289,"activeCount":70},[],{"trials":291,"activeCount":70},[],{"trials":293,"activeCount":70},[],{"trials":295,"activeCount":70},[],{"trials":297,"activeCount":70},[298],{"nctId":299,"briefTitle":300,"status":301,"phases":302,"primaryCompletion":303,"completion":303,"start":304,"enrollment":305,"conditions":306,"interventions":308},"NCT00456963","Prevention of Diabetes and Hypertension","TERMINATED",[62],"2010-03","2007-09",3000,[307,21],"Diabetes Mellitus",[286,309],"Losartan",{"trials":311,"activeCount":70},[],{"intervention":309,"totalTrials":66,"cells":313},{"EARLY_PHASE1":314,"PHASE1":316,"PHASE2":318,"PHASE3":320,"PHASE4":322,"NA":328},{"trials":315,"activeCount":70},[],{"trials":317,"activeCount":70},[],{"trials":319,"activeCount":70},[],{"trials":321,"activeCount":70},[],{"trials":323,"activeCount":70},[324],{"nctId":299,"briefTitle":300,"status":301,"phases":325,"primaryCompletion":303,"completion":303,"start":304,"enrollment":305,"conditions":326,"interventions":327},[62],[307,21],[286,309],{"trials":329,"activeCount":70},[],{"intervention":331,"totalTrials":66,"cells":332},"Carvedilol",{"EARLY_PHASE1":333,"PHASE1":335,"PHASE2":337,"PHASE3":339,"PHASE4":341,"NA":356},{"trials":334,"activeCount":70},[],{"trials":336,"activeCount":70},[],{"trials":338,"activeCount":70},[],{"trials":340,"activeCount":70},[],{"trials":342,"activeCount":70},[343],{"nctId":344,"briefTitle":345,"status":172,"phases":346,"primaryCompletion":347,"completion":347,"start":348,"enrollment":349,"conditions":350,"interventions":354},"NCT00924833","Effects of Nebivolol Versus Carvedilol on Cardiopulmonary Function at High Altitude in Healthy Subjects.",[62],"2006-11","2006-05",27,[351,352,353],"Hypoxia","Altitude","Heart Failure",[331,355],"Nebivolol",{"trials":357,"activeCount":70},[],{"intervention":355,"totalTrials":66,"cells":359},{"EARLY_PHASE1":360,"PHASE1":362,"PHASE2":364,"PHASE3":366,"PHASE4":368,"NA":374},{"trials":361,"activeCount":70},[],{"trials":363,"activeCount":70},[],{"trials":365,"activeCount":70},[],{"trials":367,"activeCount":70},[],{"trials":369,"activeCount":70},[370],{"nctId":344,"briefTitle":345,"status":172,"phases":371,"primaryCompletion":347,"completion":347,"start":348,"enrollment":349,"conditions":372,"interventions":373},[62],[351,352,353],[331,355],{"trials":375,"activeCount":70},[],{"intervention":377,"totalTrials":66,"cells":378},"Nifedipine GITS",{"EARLY_PHASE1":379,"PHASE1":381,"PHASE2":383,"PHASE3":385,"PHASE4":387,"NA":401},{"trials":380,"activeCount":70},[],{"trials":382,"activeCount":70},[],{"trials":384,"activeCount":70},[],{"trials":386,"activeCount":70},[],{"trials":388,"activeCount":70},[389],{"nctId":390,"briefTitle":391,"status":172,"phases":392,"primaryCompletion":393,"completion":394,"start":395,"enrollment":396,"conditions":397,"interventions":399},"NCT02499822","REducing Blood Pressure Variability in Essential Hypertension With RAmipril vErsus Nifedipine GITS Trial",[62],"2020-07-03","2020-11-01","2015-10",168,[21,398],"High Blood Pressure Variability",[377,400],"Ramipril",{"trials":402,"activeCount":70},[],{"intervention":400,"totalTrials":66,"cells":404},{"EARLY_PHASE1":405,"PHASE1":407,"PHASE2":409,"PHASE3":411,"PHASE4":413,"NA":419},{"trials":406,"activeCount":70},[],{"trials":408,"activeCount":70},[],{"trials":410,"activeCount":70},[],{"trials":412,"activeCount":70},[],{"trials":414,"activeCount":70},[415],{"nctId":390,"briefTitle":391,"status":172,"phases":416,"primaryCompletion":393,"completion":394,"start":395,"enrollment":396,"conditions":417,"interventions":418},[62],[21,398],[377,400],{"trials":420,"activeCount":70},[],{"intervention":422,"totalTrials":66,"cells":423},"Caffeine",{"EARLY_PHASE1":424,"PHASE1":426,"PHASE2":428,"PHASE3":430,"PHASE4":443,"NA":445},{"trials":425,"activeCount":70},[],{"trials":427,"activeCount":70},[],{"trials":429,"activeCount":70},[],{"trials":431,"activeCount":70},[432],{"nctId":433,"briefTitle":434,"status":172,"phases":435,"primaryCompletion":436,"completion":437,"start":438,"enrollment":439,"conditions":440,"interventions":441},"NCT02048215","Effect on Energy Metabolism at Cellular Level of Diet Plus Treatment With Ephedrine and Caffeine in Obesity",[61],"2001-01","2007-11","2000-02",13,[15],[422,442],"Ephedrine",{"trials":444,"activeCount":70},[],{"trials":446,"activeCount":70},[],{"intervention":442,"totalTrials":66,"cells":448},{"EARLY_PHASE1":449,"PHASE1":451,"PHASE2":453,"PHASE3":455,"PHASE4":461,"NA":463},{"trials":450,"activeCount":70},[],{"trials":452,"activeCount":70},[],{"trials":454,"activeCount":70},[],{"trials":456,"activeCount":70},[457],{"nctId":433,"briefTitle":434,"status":172,"phases":458,"primaryCompletion":436,"completion":437,"start":438,"enrollment":439,"conditions":459,"interventions":460},[61],[15],[422,442],{"trials":462,"activeCount":70},[],{"trials":464,"activeCount":70},[],{"intervention":466,"totalTrials":66,"cells":467},"Lumacaftor \u002F Ivacaftor, Orkambi® Oral",{"EARLY_PHASE1":468,"PHASE1":470,"PHASE2":472,"PHASE3":484,"PHASE4":486,"NA":488},{"trials":469,"activeCount":70},[],{"trials":471,"activeCount":70},[],{"trials":473,"activeCount":70},[474],{"nctId":475,"briefTitle":476,"status":172,"phases":477,"primaryCompletion":478,"completion":478,"start":479,"enrollment":480,"conditions":481,"interventions":483},"NCT04581408","Mutation-specific Therapy for the Long QT Syndrome",[60],"2025-04-15","2021-06-15",16,[482],"Long QT Syndrome",[466],{"trials":485,"activeCount":70},[],{"trials":487,"activeCount":70},[],{"trials":489,"activeCount":70},[],{"intervention":491,"totalTrials":66,"cells":492},"AD128",{"EARLY_PHASE1":493,"PHASE1":495,"PHASE2":497,"PHASE3":509,"PHASE4":511,"NA":513},{"trials":494,"activeCount":70},[],{"trials":496,"activeCount":70},[],{"trials":498,"activeCount":70},[499],{"nctId":500,"briefTitle":501,"status":172,"phases":502,"primaryCompletion":503,"completion":504,"start":393,"enrollment":505,"conditions":506,"interventions":508},"NCT04449133","Study of AD128 Versus Placebo in Obstructive Sleep Apnea",[60],"2020-10-30","2020-10-31",20,[507],"Obstructive Sleep Apnea",[491],{"trials":510,"activeCount":70},[],{"trials":512,"activeCount":70},[],{"trials":514,"activeCount":70},[],{"intervention":516,"totalTrials":66,"cells":517},"AD981",{"EARLY_PHASE1":518,"PHASE1":520,"PHASE2":522,"PHASE3":533,"PHASE4":535,"NA":537},{"trials":519,"activeCount":70},[],{"trials":521,"activeCount":70},[],{"trials":523,"activeCount":70},[524],{"nctId":525,"briefTitle":526,"status":172,"phases":527,"primaryCompletion":528,"completion":528,"start":529,"enrollment":19,"conditions":530,"interventions":532},"NCT05448443","Study of AD981 Versus Placebo in Obesity Hypoventilation Syndrome",[60],"2024-05-08","2022-06-21",[531],"Obesity Hypoventilation Syndrome (OHS)",[516],{"trials":534,"activeCount":70},[],{"trials":536,"activeCount":70},[],{"trials":538,"activeCount":70},[],{"intervention":540,"totalTrials":66,"cells":541},"Recombinant human growth hormone",{"EARLY_PHASE1":542,"PHASE1":544,"PHASE2":546,"PHASE3":548,"PHASE4":550,"NA":552},{"trials":543,"activeCount":70},[],{"trials":545,"activeCount":70},[],{"trials":547,"activeCount":70},[],{"trials":549,"activeCount":70},[],{"trials":551,"activeCount":70},[],{"trials":553,"activeCount":70},[554],{"nctId":555,"briefTitle":556,"status":172,"phases":557,"primaryCompletion":558,"completion":558,"start":559,"enrollment":560,"conditions":561,"interventions":564},"NCT06295341","Short Stature and Psychological Well-being",[],"2024-01-31","2023-05-10",80,[562,563],"Short Stature","Short; Stature, Psychosocial",[540],{"intervention":566,"totalTrials":66,"cells":567},"Metyrapone",{"EARLY_PHASE1":568,"PHASE1":570,"PHASE2":572,"PHASE3":574,"PHASE4":576,"NA":578},{"trials":569,"activeCount":70},[],{"trials":571,"activeCount":70},[],{"trials":573,"activeCount":70},[],{"trials":575,"activeCount":70},[],{"trials":577,"activeCount":70},[],{"trials":579,"activeCount":70},[580],{"nctId":581,"briefTitle":582,"status":172,"phases":583,"primaryCompletion":584,"completion":45,"start":585,"enrollment":505,"conditions":586,"interventions":588},"NCT05255900","Effects of Metyrapone in Patients With Hypercortisolism",[],"2025-06-30","2022-04-28",[587],"Hypercortisolism",[566],{"intervention":590,"totalTrials":66,"cells":591},"Citalopram i.v. and p.o",{"EARLY_PHASE1":592,"PHASE1":594,"PHASE2":596,"PHASE3":598,"PHASE4":600,"NA":602},{"trials":593,"activeCount":70},[],{"trials":595,"activeCount":70},[],{"trials":597,"activeCount":70},[],{"trials":599,"activeCount":70},[],{"trials":601,"activeCount":70},[],{"trials":603,"activeCount":70},[604],{"nctId":605,"briefTitle":606,"status":607,"phases":608,"primaryCompletion":609,"completion":609,"start":610,"enrollment":611,"conditions":612,"interventions":613},"NCT05795283","Potential Predictive Biological Markers of Major Depression Response to Citalopram Therapy in Anorexia Nervosa.","UNKNOWN",[],"2024-08-01","2022-08-01",123,[18],[590,614],"Citalopram p.o",{"intervention":614,"totalTrials":66,"cells":616},{"EARLY_PHASE1":617,"PHASE1":619,"PHASE2":621,"PHASE3":623,"PHASE4":625,"NA":627},{"trials":618,"activeCount":70},[],{"trials":620,"activeCount":70},[],{"trials":622,"activeCount":70},[],{"trials":624,"activeCount":70},[],{"trials":626,"activeCount":70},[],{"trials":628,"activeCount":70},[629],{"nctId":605,"briefTitle":606,"status":607,"phases":630,"primaryCompletion":609,"completion":609,"start":610,"enrollment":611,"conditions":631,"interventions":632},[],[18],[590,614],{"intervention":634,"totalTrials":66,"cells":635},"adenosine dosage",{"EARLY_PHASE1":636,"PHASE1":638,"PHASE2":640,"PHASE3":642,"PHASE4":644,"NA":646},{"trials":637,"activeCount":70},[],{"trials":639,"activeCount":70},[],{"trials":641,"activeCount":70},[],{"trials":643,"activeCount":70},[],{"trials":645,"activeCount":70},[],{"trials":647,"activeCount":70},[648],{"nctId":649,"briefTitle":650,"status":172,"phases":651,"primaryCompletion":652,"completion":652,"start":653,"enrollment":654,"conditions":655,"interventions":657},"NCT05782712","Rapid Measurement of Adenosine in Syncope Patients",[],"2022-05-31","2021-10-04",235,[656],"Syncope",[634],{"intervention":659,"totalTrials":66,"cells":660},"Dobutamine",{"EARLY_PHASE1":661,"PHASE1":663,"PHASE2":665,"PHASE3":667,"PHASE4":669,"NA":671},{"trials":662,"activeCount":70},[],{"trials":664,"activeCount":70},[],{"trials":666,"activeCount":70},[],{"trials":668,"activeCount":70},[],{"trials":670,"activeCount":70},[],{"trials":672,"activeCount":70},[673],{"nctId":674,"briefTitle":675,"status":607,"phases":676,"primaryCompletion":677,"completion":678,"start":679,"enrollment":680,"conditions":681,"interventions":682},"NCT05797584","Right Ventricular Contractile Reserve in HF",[63],"2025-03-20","2026-03-20","2019-03-20",60,[353],[659],{"intervention":684,"totalTrials":66,"cells":685},"Proteomic analyses",{"EARLY_PHASE1":686,"PHASE1":688,"PHASE2":690,"PHASE3":692,"PHASE4":694,"NA":696},{"trials":687,"activeCount":70},[],{"trials":689,"activeCount":70},[],{"trials":691,"activeCount":70},[],{"trials":693,"activeCount":70},[],{"trials":695,"activeCount":70},[],{"trials":697,"activeCount":70},[698],{"nctId":699,"briefTitle":700,"status":607,"phases":701,"primaryCompletion":702,"completion":703,"start":704,"enrollment":705,"conditions":706,"interventions":709},"NCT05749107","In-depth Characterization of Atriogenic Secondary Tricuspid Regurgitation Due to Atrial Fibrillation",[],"2024-12-02","2025-11-02","2022-12-02",1050,[707,708],"Heart Valve Incompetence","Atrial Fibrillation, Persistent",[684]]